Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aquestive Therapeutics, Inc. - Common Stock (NQ:AQST)

2.925 +0.090 (+3.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,002,989
Open 2.810
Bid (Size) 2.890 (2)
Ask (Size) 3.040 (5)
Prev. Close 2.835
Today's Range 2.770 - 2.955
52wk Range 2.200 - 5.800
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Concludes FDA Application For Allergy Drug With Encouraging Pediatric Trial Data
Aquestive's Anaphylm sublingual film met key pediatric study goals, supporting its NDA submission to the FDA for potential approval in 2025. 
Via Benzinga
Exposures Product Safety

Performance

YTD
-20.3%
-20.3%
1 Month
+0.9%
+0.9%
3 Month
-5.6%
-5.6%
6 Month
-48.1%
-48.1%
1 Year
-12.9%
-12.9%

More News

Read More
Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Stock Dips After-Hours On Q4 Miss — Retail Eyes Silver Linings
Via Stocktwits
Curious about the stocks that are showing activity after the closing bell on Wednesday?
Via Chartmill
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Conferences in March
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For March 5, 2025
Via Benzinga
Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside
Via Benzinga
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
Via Benzinga
Exposures Product Safety
Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™
From Aquestive Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Aquestive Therapeutics, Inc. - Common Stock publicly traded?
Yes, Aquestive Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Aquestive Therapeutics, Inc. - Common Stock trade on?
Aquestive Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aquestive Therapeutics, Inc. - Common Stock?
The ticker symbol for Aquestive Therapeutics, Inc. - Common Stock is AQST on the Nasdaq Stock Market
What is the current price of Aquestive Therapeutics, Inc. - Common Stock?
The current price of Aquestive Therapeutics, Inc. - Common Stock is 2.925
When was Aquestive Therapeutics, Inc. - Common Stock last traded?
The last trade of Aquestive Therapeutics, Inc. - Common Stock was at 04/30/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.